SOLID TUMORS (PHASE 1)
Clinical trials for SOLID TUMORS (PHASE 1) explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS (PHASE 1) trials appear
Sign up with your email to follow new studies for SOLID TUMORS (PHASE 1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug ADCE-B05 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ADCE-B05 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. About 180 participants will receive the drug to see how well it is t…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated May 26, 2026 08:37 UTC
-
New drug targets hard-to-treat tumors with missing gene
Disease control Recruiting nowThis early-phase study tests a new drug called ABSK131 in people with advanced solid tumors that have a missing MTAP gene. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors or slow their growth. About 266 adults who have tried other tr…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New pill targets tough cancers with BRAF mutation in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug called HSK42360-Na in adults with advanced solid tumors that have a specific BRAF V600 gene change. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 159 partici…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis early-phase study tests a new oral drug, AN9025, in people with advanced solid tumors that have specific RAS gene mutations. The main goal is to check the drug's safety and find the right dose. About 91 participants will take the drug daily and be monitored closely for side …
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC